Suppr超能文献

CHEK2 基因突变可独立增加保加利亚乳腺癌患者的死亡风险。

CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients.

机构信息

Institute of Plant physiology and Genetics, Department of Molecular Genetics, Bulgarian Academy of Sciences, Acad. G. Bonchev Street, Bldg. 21, 1113 Sofia, Bulgaria.

出版信息

Neoplasma. 2012;59(6):622-30. doi: 10.4149/neo_2012_079.

Abstract

Checkpoint kinase 2 (CHEK2) is a DNA damage-activated protein kinase implicated in cell cycle checkpoint control. The significance of CHEK2 alterations for breast cancer incidence and clinical behavior is not clear. In this study we determined the mutational spectrum and the level of promoter hypermethylation of CHEK2 gene in a group of 145 Bulgarian patients with breast cancer. A special emphasis was put on the clinical impact of CHEK2 alterations for breast cancerogenesis. PCR-SSCP-sequencing analysis of the entire coding sequence of CHEK2 gene was performed to estimate the mutational profile of tumor samples. Methylation-sensitive SSCP was applied to determine the methylation status in CpG clusters implicated in CHEK2 silencing. Clinical significance of CHEK2 alterations was evaluated using standard statistical methods. Mutations in CHEK2 were identified in 9.65 % of the patients. Two novel missense substitutions Thr476Met (C >T) and Ala507Gly (C>G), and a novel silent variant Glu79Glu (A>G) were registered. However, hypermethylation was not found in any of the studied cases. Comparison with clinical characteristics showed that CHEK2 positive women have predominantly lobular type of breast carcinoma (р=0.04) and PR+ status (p=0.092). CHEK2 mutations correlated significantly with ATM+ status (p=0.046). All patients with the Glu79Glu variant were progesterone receptor positive (p=0.004). A decrease in overall survival (p = 0.6301) and a threefold increased independent risk of death (HR = 3.295, 95%CI 0.850-12.778, p = 0.085) in CHEK2+patients was found. Our data indicate the significance of CHEK2 gene alterations in contrast to promoter hypermethylation in breast cancerogenesis. Specificity of CHEK2 mutational profile for the Bulgarian population was found. Though CHEK2 mutational status correlated with more favorable clinical characteristics, including positive progesterone receptor and lobular histological type, it independently increased the risk of death in these patients.

摘要

细胞周期检查点激酶 2(CHEK2)是一种 DNA 损伤激活的蛋白激酶,参与细胞周期检查点控制。CHEK2 改变对乳腺癌的发生和临床行为的意义尚不清楚。在这项研究中,我们测定了 145 例保加利亚乳腺癌患者的 CHEK2 基因的突变谱和启动子超甲基化水平。特别强调了 CHEK2 改变对乳腺癌发生的临床影响。通过 PCR-SSCP 测序分析 CHEK2 基因的整个编码序列,估计肿瘤样本的突变谱。应用甲基化敏感 SSCP 来确定与 CHEK2 沉默相关的 CpG 簇的甲基化状态。使用标准统计方法评估 CHEK2 改变的临床意义。在 9.65%的患者中发现了 CHEK2 突变。鉴定出 2 种新的错义替换 Thr476Met(C>T)和 Ala507Gly(C>G),以及 1 种新的沉默变体 Glu79Glu(A>G)。然而,在研究的任何病例中均未发现超甲基化。与临床特征的比较表明,CHEK2 阳性女性主要具有小叶型乳腺癌(р=0.04)和 PR+状态(p=0.092)。CHEK2 突变与 ATM+状态显著相关(p=0.046)。所有携带 Glu79Glu 变异的患者孕激素受体均为阳性(p=0.004)。在 CHEK2+患者中,总生存时间下降(p = 0.6301),死亡风险独立增加三倍(HR = 3.295,95%CI 0.850-12.778,p = 0.085)。我们的数据表明,CHEK2 基因改变在乳腺癌发生中与启动子超甲基化相比具有重要意义。发现了 CHEK2 突变谱对保加利亚人群的特异性。尽管 CHEK2 突变状态与更有利的临床特征相关,包括孕激素受体阳性和小叶组织学类型,但它独立增加了这些患者的死亡风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验